Daily Cardiology Research Analysis
Three impactful cardiology studies this week challenge and refine routine practice. A large target-trial–emulated analysis found early beta-blocker initiation after PCI for stable CAD with preserved LVEF was linked to higher mortality without reducing cardiovascular events. In heart failure, a 2,050-patient cohort showed transferrin saturation—not ferritin—tracks adverse outcomes and ties to inflammatory/lipid pathways, while real-world data support SGLT2 inhibitor benefits in patients older tha
Summary
Three impactful cardiology studies this week challenge and refine routine practice. A large target-trial–emulated analysis found early beta-blocker initiation after PCI for stable CAD with preserved LVEF was linked to higher mortality without reducing cardiovascular events. In heart failure, a 2,050-patient cohort showed transferrin saturation—not ferritin—tracks adverse outcomes and ties to inflammatory/lipid pathways, while real-world data support SGLT2 inhibitor benefits in patients older than 80 without safety penalties.
Research Themes
- De-implementation of routine beta-blockers after PCI in stable CAD with preserved LVEF
- Refining iron deficiency phenotyping in heart failure using transferrin saturation and proteomics
- Effectiveness and safety of SGLT2 inhibitors in very elderly heart failure patients
Selected Articles
1. Transferrin Saturation, Serum Iron, and Ferritin in Heart Failure: Prognostic Significance and Proteomic Associations.
In 2,050 heart failure patients, low transferrin saturation and serum iron, but not ferritin, were associated with higher all-cause mortality, with stronger effects in HFpEF. Proteomics linked low TSAT to inflammatory and lipid metabolism pathways, suggesting biological plausibility and a need to re-evaluate iron deficiency criteria.
Impact: Findings challenge current ferritin-centric definitions of iron deficiency and support TSAT as a superior prognostic marker, potentially altering screening and treatment selection for IV iron in HF.
Clinical Implications: Prioritize TSAT in iron status assessment for HF patients, especially HFpEF, and consider TSAT-guided selection for iron therapy. Reassess reliance on ferritin alone in clinical algorithms.
Key Findings
- Ferritin levels were not associated with outcomes, whereas low TSAT and serum iron predicted higher all-cause mortality.
- Associations of low TSAT with adverse outcomes were stronger in HFpEF than in HFrEF/HFmrEF.
- Proteomic profiling (4,928 proteins) linked low TSAT to inflammatory and lipid metabolism pathways.
Methodological Strengths
- Prospective, well-characterized cohort (PHFS) with 2,050 participants across LVEF spectra
- Comprehensive proteomic analysis using an aptamer-based platform (SOMAScan v4)
Limitations
- Observational design precludes causal inference and treatment effects
- Single cohort; external validation and standardized TSAT thresholds were not established
Future Directions: Validate TSAT-centric definitions in external cohorts and test TSAT-guided iron therapy in randomized trials, including HFpEF. Investigate proteome-anchored mechanisms linking iron handling, inflammation, and outcomes.
BACKGROUND: Iron deficiency (ID) is currently defined as a serum ferritin level <100 or 100 to 299 ng/mL with transferrin saturation (TSAT) <20%. Serum ferritin and TSAT are currently used to define absolute and functional ID. However, individual markers of iron metabolism may be more informative than current arbitrary definitions of ID. METHODS: We assessed prognostic associations of ferritin, serum iron, and TSAT among 2050 participants with heart failure (HF) with reduced/mid-range (n=1821) or preserved (n=229) left ventricular ejection fraction enrolled in the PHFS (Penn HF Study), a prospective cohort study. We measured 4928 plasma proteins using an aptamer-based assay (SOMAScanv4) and assessed prognostic and proteomic associations of markers of iron metabolism. RESULTS: Ferritin concentrations were not associated with outcomes, whereas low TSAT and serum iron were associated with the risk of all-cause death (TSAT: standardized hazard ratio, 0.84 [95% CI, 0.76-0.93]; CONCLUSIONS: Low TSAT, but not ferritin concentrations, is significantly associated with adverse outcomes in HF. Low TSAT is more strongly associated with outcomes in HF with preserved ejection fraction. Pathways related to inflammation and lipid metabolism are associated with low TSAT in HF.
2. Beta-Blockers After PCI for Stable Coronary Artery Disease and Preserved Left Ventricular Ejection Fraction.
In a propensity-matched emulation of a target trial, early beta-blocker initiation after PCI for stable CAD with preserved LVEF was associated with higher all-cause mortality and no reduction in MI, stroke, HF, or AF hospitalizations over 5 years. Hypotension-related admissions were more frequent with beta-blockers.
Impact: The study challenges routine post-PCI beta-blocker use in stable CAD with preserved LVEF and supports de-implementation or more selective prescribing.
Clinical Implications: Avoid routine early beta-blocker initiation after PCI in stable CAD with preserved LVEF; reserve for clear indications (e.g., arrhythmias, angina not controlled by other agents) and monitor for hypotension.
Key Findings
- Early beta-blocker initiation was associated with higher all-cause mortality (HR 1.11) over 5 years.
- No significant differences in hospitalizations for MI, stroke, HF, or AF/flutter between groups.
- Higher hospitalization for hypotension with beta-blockers (HR 1.10); falsification endpoints showed no spurious associations.
- Results were consistent across multiple sensitivity analyses.
Methodological Strengths
- Target trial emulation with incident user design and 1:1 propensity score matching
- Large real-world cohort (TriNetx) with intention-to-treat analysis over 5 years and falsification endpoints
Limitations
- Observational design; potential residual confounding and misclassification of indications/adherence
- Lack of granular data on dose-titration and symptom burden influencing prescribing
Future Directions: Randomized trials or high-quality pragmatic trials targeting this population; subgroup analyses (e.g., ischemia burden, arrhythmia) to refine indications.
BACKGROUND: Limited data exist on the long-term impact of beta-blocker therapy after percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (CAD) and preserved left ventricular ejection fraction (LVEF). OBJECTIVES: The aim of the study was to evaluate the effects of early beta-blocker initiation vs no initiation following PCI in patients with stable CAD and preserved LVEF. METHODS: This retrospective cohort study employed target trial emulation and incident user design, utilizing the TriNetx database (2009-2024). Early beta-blocker initiation (within days 1 and 7) was compared with no initiation using 1:1 greedy propensity score matching. The outcomes included all-cause mortality, hospitalization for myocardial infarction, heart failure, atrial fibrillation/flutter, stroke, and safety endpoints. Hospitalization for bone fracture and acute appendicitis served as falsification endpoints. In the intention-to-treat analysis, outcomes were analyzed over 5 years using Cox-proportional hazards. RESULTS: Out of 11,681 matched patients per group, beta-blocker therapy was associated with increased all-cause mortality (HR: 1.11 [95% CI: 1.09-1.18]). No significant differences were found in hospitalization for myocardial infarction (HR: 1.03 [95% CI: 0.97-1.09]), stroke (HR: 0.98 [95% CI: 0.91-1.05]), heart failure (HR: 0.99 [95% CI: 0.95-1.03]), and atrial fibrillation/flutter (HR: 0.97 [95% CI: 0.93-1.01]). Hospitalization for hypotension was higher with beta-blockers (HR: 1.10 [95% CI: 1.06-1.14]). Hospitalization for bone fracture (HR: 1.02 [95% CI: 0.85-1.22]) and acute appendicitis (HR: 1.17 [95% CI: 0.95-1.45]) showed no significant associations. Several sensitivity analyses showed consistent results. CONCLUSIONS: Early beta-blocker initiation after PCI for stable CAD with preserved LVEF was associated with higher mortality, with no impact on cardiovascular events.
3. The efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients aged over 80 years with heart failure.
In 1,559 heart failure patients aged >80, SGLT2 inhibitors reduced all-cause mortality and HF hospitalization at 1 year without increasing adverse safety events. Benefits were consistent across frailty, nutritional risk, BMI, LVEF, and diabetes subgroups.
Impact: Extends SGLT2 inhibitor evidence to very elderly and frail populations underrepresented in RCTs, supporting broader real-world adoption.
Clinical Implications: Consider SGLT2 inhibitors for patients >80 with HF regardless of frailty, low BMI, or low nutritional status, with routine monitoring; reassures on safety in this population.
Key Findings
- SGLT2 inhibitors reduced the 1-year composite of all-cause death and HF hospitalization (31.6% vs 47.3%).
- Adjusted HRs favored SGLT2i for all-cause death (0.58) and HF hospitalization (0.69).
- No increase in safety composite events (ischemic stroke, UTI, dehydration) with SGLT2i (adjusted HR 0.80).
- Benefits were consistent across subgroups including frailty, nutritional risk, BMI, LVEF, and diabetes.
Methodological Strengths
- Large real-world cohort of very elderly HF patients with multivariable adjustment
- Comprehensive subgroup analyses across frailty and nutritional status strata
Limitations
- Retrospective single-center design with potential residual confounding and selection bias
- Treatment allocation not randomized; medication adherence and dosing details limited
Future Directions: Pragmatic randomized trials in very elderly HF patients; head-to-head comparisons across SGLT2i agents and optimization with polypharmacy in frailty.
AIMS: Sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) have demonstrated effectiveness in reducing cardiovascular death and heart failure hospitalization (HFH). However, the efficacy and safety of SGLT2 inhibitors in elderly patients with poor general status, such as very low bodyweight or low nutritional status, who are not included in randomized controlled trials, has not yet been examined. In a real-world setting, the introduction of SGLT2 inhibitors to such elderly patients is a very difficult decision to make. We therefore examined the efficacy and safety of these drugs in elderly heart failure patients in a real-world setting. METHODS AND RESULTS: In Kokura Memorial Hospital, a retrospective study was conducted on 1559 patients over 80 years old hospitalized for HF between 2018 and 2023. Among them, 1326 were included in the non-SGLT2i group and 233 in the SGLT2i group. A multivariate Cox regression model was used to compare the risk of primary composite outcome (all-cause death and HFH) and secondary safety composite outcome (ischaemic stroke, urinary tract infection and dehydration) at 1 year post-discharge between the two groups. The cumulative 1 year incidence of the composite outcome was significantly higher in the non-SGLT2i group (47.3% vs. 31.6%, P < 0.01). SGLT2 inhibitors independently reduced the risk of all-cause death [adjusted hazard ratio (HR): 0.58, 95% confidence interval (CI): 0.39-0.87, P < 0.01] and HFH (adjusted HR: 0.69, 95% CI: 0.52-0.91, P < 0.01), whereas the risk of safety composite events was not increased (adjusted HR: 0.80, 95% CI: 0.49-1.29, P = 0.36). Subgroup analysis showed no significant interactions between age, diabetes, body mass index, left ventricular ejection fraction, clinical frailty scale, geriatric nutritional risk index and SGLT2 inhibitors consistently reduced composite outcomes across all strata. Similarly, SGLT2 inhibitors did not increase safety composite outcomes at any strata. CONCLUSIONS: SGLT2 inhibitors reduce the risk of all-cause death and HFH without increasing adverse events, even in patients over 80 years old. It may be that SGLT2 inhibitors are effective and safe in patients who are basically hesitant to be introduced to SGLT2 inhibitors, such as those with high frailty, low nutritional status or very low bodyweight.